Fujirebio announced that it had received the Japanese Society of Clinical Chemistry Technology Award. This marks the 8th time it has received the award in the past 10 years.
Fujirebio Inc. announced that it had received the Japanese Society of Clinical Chemistry Technology Award. The award recognized its Lumipulse Presto iTACT HBcrAg initiative, which uses Fujirebio’s proprietary iTACT technology in an in vitro diagnostic product that measures HBcrAg in serum.
The company is part of H.U. Group Holdings and has pursued many years of research and development and the provision of testing solutions in the clinical laboratory testing field. The award is described as one example of the group’s accumulated technological capabilities.
H.U. Group operates multiple businesses in the clinical laboratory testing and healthcare services fields, and has stated its policy of contributing to the creation of new value in testing and diagnostics through this award.
The announcement also outlines the background to the award, the group’s business operations and its future outlook.